The management of Clostridium difficile infection: antibiotics, probiotics and other strategies.
Clostridium difficile-associated disease remains an important nosocomial infection associated with significant morbidity and mortality. In recent years, there has been an upward trend in the incidence of this condition with continuing high rates of recurrent disease with available treatment regimens. In this article, we review the current literature on the management of C. difficile-associated disease (CDAD). The potential role for alternative therapeutic options for the treatment of CDAD, including the use of bacteriotherapy in the form of probiotics, immunotherapy and ion-exchange resins as well as new drugs under investigation is explored. The evidence indicates a need for innovative approaches to the management of this condition. The combined use of antibiotic therapy and replacement of gut microbiota using probiotics remains promising and we suggest a multi-pronged approach in the management of this challenging infection.
Senok
A C
AC
Department of Clinical Sciences, College of Medicine, University of Sharjah, United Arab Emirates.
Rotimi
V O
VO
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016360:Clostridioides difficile; D003015:Clostridium Infections / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D007475:Ion Exchange Resins / Q000627:therapeutic use; D019936:Probiotics / Q000627:therapeutic use; D012307:Risk Factors
D000900:Anti-Bacterial Agents; D007475:Ion Exchange Resins